Home Cart Sign in  
Chemical Structure| 1286279-29-5 Chemical Structure| 1286279-29-5

Structure of BMS-813160
CAS No.: 1286279-29-5

Chemical Structure| 1286279-29-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-813160 is a CCR2/5 dual antagonist that effectively blocks CCR2 and CCR5 signaling pathways, suitable for research on inflammatory and immune-related diseases.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-813160

CAS No. :1286279-29-5
Formula : C25H40N8O2
M.W : 484.64
SMILES Code : CC(N[C@H]1[C@@H](N2C([C@@H](NC3=NC=NC4=CC(C(C)(C)C)=NN43)CC2)=O)CC[C@@H](NC(C)(C)C)C1)=O
MDL No. :MFCD31540731

Safety of BMS-813160

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of BMS-813160

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 cells 0.8±0.8 nM To assess the chemotaxis inhibitory effect of BMS-813160 on CCR2 ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758
human peripheral T cells 3.6±1.8 nM To determine the binding affinity of BMS-813160 to CCR5 ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758
human peripheral blood mononuclear cells 6.2±2.7 nM To determine the binding affinity of BMS-813160 to CCR2 ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Human-CCR2 knock-in mouse Oral 10, 50, 160 mg/kg Twice daily for 48 hours To evaluate the role of BMS-813160 in inhibiting the migration of inflammatory monocytes and macrophages, showing a dose-dependent significant reduction in inflammatory cell infiltration ACS Med Chem Lett. 2021 Oct 15;12(11):1753-1758

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.32mL

2.06mL

1.03mL

20.63mL

4.13mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories